Daclizumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | CD25 |
| Clinical data | |
| Trade names | Zinbryta (multiple sclerosis) Zenapax (acute transplant rejection, discontinued in 2009) |
| AHFS/Drugs.com | zinbryta |
| Pregnancy category |
|
| Routes of administration |
Subcutaneous injection (MS) Intravenous (transplant rejection, discontinued) |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | 90% |
| Metabolism | Proteases |
| Biological half-life | 21 days (11–38 days) |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C6332H9808N1678O1989S42 |
| Molar mass | 142,612.1 g/mol |
  (what is this?)
|
|
Daclizumab (trade name Zinbryta, by Biogen) is a therapeutic humanized monoclonal antibody used for the treatment of adults with relapsing forms of multiple sclerosis (MS). Daclizumab works by binding to CD25, the alpha subunit of the IL-2 receptor of T-cells.
It was formerly marketed under the trade name Zenapax to prevent acute rejection in people with kidney transplants along with cyclosporine and corticosteroids but marketing of the drug for that purpose was discontinued in 2009 due to lack of market demand.
Daclizumab is used to treat adults with relapsing forms of multiple sclerosis. It is administered subcutaneously.
In clinical trials it showed 45% decrease in annualized relapse rate, a 41% reduction in the proportion of patients who relapsed, and a 54% reduction in the number of new lesions.
Daclizumab was approved and used to prevent acute rejection of kidney transplant, along with cyclosporine and corticosteroids. For that indication, side effects with a frequency of at least 10% included sleeplessness, tremor, headache, arterial hypertension, dyspnoea, gastrointestinal side effects and oedema. In rare cases, the drug could cause severe anaphylaxis.
In the US, daclizumab is contraindicated in people with liver impairment, including significantly elevated liver enzymes (ALT, AST) and autoimmune hepatitis. The European Medicines Agency has approved the drug without any contraindications apart from known hypersensitivity, but required Biogen to implement a hepatic risk management guide for physicians.
...
Wikipedia